BSX won’t recover, but don’t fret, Ultimate Stock Alerts (google search for them now)
just gave me a replacement and I am going to buy
NSPR has a unique patented mesh technology for stents. There has been no innovation in stents for over 15 years. Premium price soild sales ramping up in Europe. Major Docs in Europe are supporting this new stent with a mesh. The clinical data to date looks very compelling with a P value of .03 ....So it is stat sig. They should easily be able to gain 20% ..30% of the European market which is $500 million. Over here with a partner on DES stents that is a multi billion dollar market place this looks like a $500 million dollar a year company to me in the early stages that someone could snap up on the cheap for $4 bucks a sharewhich puts it at $168 market cap or even $8 a share which puts it at $336 million. Any BSX folks have any thoughts? The guy running NSPR is an ex-Executive from BSX?
I started looking into this thing NSPR it has some interesting data ...And some good patented stent technology they could be an acquistion target but it will take a while before they make any kind of big splash.. They will probably get some good sales in Europe on the Cartoid Stents.. they will have to partner to a dent over here in the US ...Looked at their presentation and they are looking for a partner now?
NSPR? They have some new stent mesh technology... they are going to partner it with someone? BSX? The CEO is an ex BSX executive? Pretty impressive group of executives at NSPR? Just wondering what some BSX folks might know about the mesh vs standard DES? They have a P value of .03 which is stat sig. Any thoughts? Thanks
I must admit that were JNJ to be the acquirer of both BSX and what is left of Guidant, it would be a rich joke on Nicholas, Tobin and Best, the clowns who outbid JNJ to acquire Guidant. You'd think that this trio would have asked themselves whether there was something counterintuitive a bout their outbidding the far better financed and better brained JNJ for Gudiant? At your price of $26, JNJ would be getting both assets at a steep discount to where both traded on the eve of the BSX "coup." Indeed, today BSX is worth less than it paid for Guidant ($28 billion, more or less).
Yes, BSX could attract bids. We'll see.
Given the JNJ settlement news and the strong move in BSX shares, it's surprising that the board is so silent. I take that as a good sign, evidence that the shares long wandering in the wilderness has alienated pretty much everyone. I started buying shares around $18 (that was 8 years ago after what I thought was the worst impact of the Guidant acquisition), but most of my shares were bought under $7 in 2010. Then I just sat and took the pain. Now I want to see what BSX can do without JNJ looming over it.